Evidence map›Paper›PMID 38698605›Full record

ArticlePharmacopsychiatry2024

Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group.

Hannah B Maier, Anton Borchert, Alexandra Neyazi, Nicole Moschny, Rasmus Schülke, Gabriel L Bundies, Thorsten Folsche, Anastasia Gaspert, Johanna Seifert, Stefan Bleich and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacopsychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hannah B MaierDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Anton BorchertDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Alexandra NeyaziDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Nicole MoschnyDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Rasmus SchülkeDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Gabriel L BundiesDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Thorsten FolscheDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Anastasia GaspertDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Johanna SeifertDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Stefan BleichDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Maike Scherf-ClavelDepartment of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany.
Stefan UntereckerDepartment of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany.
Jürgen DeckertDepartment of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany.
Helge FrielingDepartment of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Germany.
Heike WeberDepartment of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApproximately 15-25% of depressed patients suffer from difficult-to-treat depression (DTD). Patients with DTD require a thorough examination to avoid the oversight of treatable (psychiatric/somatic) comorbidities or (pseudo-)resistance to antidepressant drugs (ADs). Polymorphisms of the cytochrome P450 (CYP) enzymes 2D6 and 2C19, which play a major role in the metabolism of ADs, may contribute to resistance to ADs. Patients with DTD might benefit from electroconvulsive therapy (ECT).

methodsWe enrolled 109 patients with DTD and 29 untreated depressed controls (UDC). We assessed risk phenotypes, comorbidities, and treatment, including ECT. We also performed pharmacokinetic analyses of CYP2D6 and CYP2C19.

resultsDTD patients significantly more often suffered from comorbid psychiatric diseases, especially ICD-10: F40-F48 (DTD:40.4%, UDC:17.2%, OR 11.87,

conclusionPatients with DTD appear to experience comorbid neurotic stress and somatoform disorders (ICD-10: F40 - F48) more frequently. Therefore, a comprehensive differential diagnosis is crucial when patients do not respond sufficiently to antidepressant medication. Genotyping

Indexed as

Antidepressive AgentsComorbidityDepressive Disorder, Treatment-ResistantDisease SusceptibilityElectroconvulsive TherapyPhenotypeAdolescentAdultAgedCase-Control StudiesCohort StudiesCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6FemaleHumansMaleAntidepressive AgentsCYP2C19 protein, humanCYP2D6 protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6

Identifiers

PMID38698605
PMCPMC11233224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.